176 related articles for article (PubMed ID: 33794195)
1. The use of aptamers in prostate cancer: A systematic review of theranostic applications.
Campos-Fernández E; Oliveira Alqualo N; Moura Garcia LC; Coutinho Horácio Alves C; Ferreira Arantes Vieira TD; Caixeta Moreira D; Alonso-Goulart V
Clin Biochem; 2021 Jul; 93():9-25. PubMed ID: 33794195
[TBL] [Abstract][Full Text] [Related]
2. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
3. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
4. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
6. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E
Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
[TBL] [Abstract][Full Text] [Related]
9. Metal-Labeled Aptamers as Novel Nanoprobes for Imaging Mass Cytometry Analysis.
Yu Y; Dang J; Liu X; Wang L; Li S; Zhang T; Ding X
Anal Chem; 2020 May; 92(9):6312-6320. PubMed ID: 32208602
[TBL] [Abstract][Full Text] [Related]
10. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
11. RNA aptamer-mediated gene therapy of prostate cancer: lessons from the past and future directions.
Arese M; Mahmoudian M; Bussolino F
Expert Opin Drug Deliv; 2023; 20(11):1609-1621. PubMed ID: 38058168
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Lupold SE; Hicke BJ; Lin Y; Coffey DS
Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
[TBL] [Abstract][Full Text] [Related]
13. Aptamers as Theragnostic Tools in Prostate Cancer.
Cruz-Hernández CD; Rodríguez-Martínez G; Cortés-Ramírez SA; Morales-Pacheco M; Cruz-Burgos M; Losada-García A; Reyes-Grajeda JP; González-Ramírez I; González-Covarrubias V; Camacho-Arroyo I; Cerbón M; Rodríguez-Dorantes M
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008950
[TBL] [Abstract][Full Text] [Related]
14. Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing.
Savory N; Abe K; Sode K; Ikebukuro K
Biosens Bioelectron; 2010 Dec; 26(4):1386-91. PubMed ID: 20692149
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
16. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens.
Mallikaratchy P
Molecules; 2017 Jan; 22(2):. PubMed ID: 28146093
[TBL] [Abstract][Full Text] [Related]
18. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
19.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
20. A theranostic "SMART" aptamer for targeted therapy of prostate cancer.
de Franciscis V
Mol Ther; 2014 Nov; 22(11):1886-8. PubMed ID: 25365986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
